Novo Nordisk now expects sales to grow 13% to 21% in constant currencies this year, from 16% to 24% previously. Operating profit should grow 16% to 24% compared with a previous target of 19% to 27%.

The FDA has accepted for review the New Drug Application for a 25mg oral formulation of semaglutide for chronic weight management.